European Union Identified Covid-19 Vaccine Shot of Johnson and Johnson Possibly Linked with Blood Clotting


The drug regulator of the European Union has identified a possible link between the rare cases of the blood clotting in the deep veins and the novel corona virus vaccine developed by Johnson and Johnson, and the European Medicines Agency has also recommended the condition for being listed as a side-effect of the covid-19 vaccine shot.

The European Medicines Agency (EMA) has said that, the immune thrombocytopenia (ITP), which has been a bleeding disorder that has been caused by the body, due to wrongly attacking the platelets, that will be added as an adverse reaction along with an unknown frequency to the covid-19 vaccine product information of Johnson and Johnson and also to the covid-19 vaccine developed by AstraZeneca.

The company ‘Johnson and Johnson’ said, as the chances of experiencing these conditions had been very low, and the information of the product is going to be updated accordingly as it has been continuing to work closely with the healthcare authorities including the EMA.

READ  US FDA Approves Two New Drug Applications Of Lupin

The company said, they have strongly support raising the awareness of the symptoms and signs of the rare events for the purpose of ensuring that, they can quickly be identified and treated effectively, and both the corona virus vaccines developed by AstraZeneca and Johnson and Johnson, have previously been associated with a very rare combination of the blood clotting along with the low counts of platelets, which are generally known as thrombosis.